Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fifty 410 vs NewSelf

By GLP-1 ScorecardUpdated

Fifty 410
Site position #213

Lower grade

NewSelf
Site position #39

Higher grade

Score comparison

NewSelf has the higher recorded score — 79.8/100 to 66.3/100.

NewSelf grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Round-$100 semaglutide, $144 tirzepatide, verified and available in all 50 states.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueNewSelf +7
86
93
Dose & formulationNewSelf +8
72
80
Clinical oversightEven
55
55
Labs & monitoringNewSelf +29
53
82
FulfillmentNewSelf +16
71
87
Contract termsNewSelf +48
37
85
Fifty 410 · top barNewSelf · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricFifty 410NewSelf
WeighScore66.3/10079.8/100
GradeCC+
Site position#213#39
Semaglutide$99/mo (all doses, compounded)$100/mo
Tirzepatide$133/mo (starting dose, compounded)$144/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Fifty 410

Site position #213 · C

FDAWarning letter issued to Aspen Aesthetics dba Fifty 410 in February 2026. See the FDA warning-letter database.

Strengths

  • Transparent public pricing from 99 dollars per month for semaglutide
  • No membership or subscription; pay only for what you need
  • Compounded by FDA-registered 503A and 503B pharmacies
  • Fast 24 to 48 hour provider review
  • Free one to two day shipping

What to consider

  • Does not bill insurance directly
  • Compounded GLP-1 is not an FDA-approved finished drug
  • Specific clinician credentials are not publicly disclosed
  • Served-states list is not published on the site
  • FDA issued Aspen Aesthetics dba Fifty 410 a warning letter in February 2026; the letter is public in FDA's warning-letter database
NewSelf

Site position #39 · C+

FDAWarning letter issued to NewSelf Limited dba NewSelf in February 2026. See the FDA warning-letter database.

Strengths

  • $100 sema / $144 tirz
  • All 50 states, LegitScript-verified
  • Both molecules

What to consider

  • Injection-only
  • Labs/monitoring detail sparse
  • Limited brand history

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard